Investor Relations

diaDexus (DDXS.OB), based in South San Francisco, California, develops and commercializes proprietary diagnostic products addressing unmet needs in cardiovascular disease (CVD). The Company’s two diagnostic products are the only FDA-cleared Lp-PLA2 blood tests to uncover the hidden risk of cardiovascular disease.

  • The PLAC® Test ELISA Kit is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States.
  • The PLAC® Test for Lp-PLA2 Activity is to be used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of coronary heart disease in patients with no prior history of cardiovascular events, which represents approximately 75% of coronary heart disease patients.

The company also has heart failure biomarkers for development.

.

Fact Sheet PDF

View all »   RSSRecent Releases

Feb 24, 2015
diaDexus, Inc. Announces Appointment of John Curnutte, M.D., Ph.D. to Its Board of Directors

Jan 27, 2015
diaDexus, Inc. Appoints Mika Newton to Lead Clinical Development Service Business



View all »Events & Presentations

Mar 11, 2015 at 1:30 PM PT
4th Quarter and Full Year 2014 Financial Results Conference Call

Mar 22, 2015
EAS (European Atherosclerosis Society) Annual Congress

 

©2015 diaDexus, Inc. | diaDexus and PLAC are U.S. Registered Trademarks of diaDexus, Inc.